Prolongation of Mysimba® distribution agreement
Oslo, 20 October 2026 - Navamedic ASA has secured a five-year prolongation of the Nordic rights to Mysimba® - an oral tablet prescribed for the treatment of obesity.
"We are pleased to announce a prolongation of the Nordic rights to distribute and market Mysimba®. We are also pleased to collaborate with Azurity who as the new global owner of Mysimba will increase the support to local partners like Navamedic," says Lars Minor, Chief Executive Officer of Navamedic.
Navamedic has distributed Mysimba® (naltrexone/bupropion) in the Nordic region since 2017 under a long-term exclusive agreement with the product's previous owners. In 2026, the product and associated rights were acquired by Azurity Pharmaceuticals.
"Mysimba® remains an important product to Navamedic, and we appreciate the new partnership with Azurity and jointly aim to ensure continued availability of Mysimba® in the Nordic markets. With the renewal of this agreement and new partnership with Azurity, we look forward to exploring further collaboration opportunities for additional products in the future," Lars Minor concludes.
Navamedic and Azurity have agreed to extend the existing distribution agreement on largely similar terms for additional five years with an upfront licensing fee. The effective date of the agreement is 26 April 2027, and the revised terms of the agreement are implemented from this date.
For further information, please contact:
Lars Minor, CEO, mobile: +45 20 89 62 00 Nils Ole Krekling, CFO, mobile: +47 924 24 016
About Navamedic Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.